SecBot SecBot
6-K ·Filed Jul 1, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001575872-26-000475
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine filing with no material new information. Traders should monitor upcoming earnings or press releases for any operational or financial updates.

DirectionNeutral
Confidencelow
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$13.99
T+0 close · Jul 1, 2026 · via day close
Latest settled
−15.94%
T+20 · $11.76
Vs SPY
−13.75%
α at T+20
Next horizon
T+60
due 8w ago
  1. T+0 · Jul 1 $13.99entry
  2. T+1 · 5mo ago +2.79%α +2.92% · $14.38
  3. T+5 · 4mo ago +4.57%α +4.31% · $14.63
  4. T+20 · 4mo ago −15.94%α −13.75% · $11.76
  5. T+60 · due 8w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's Laboratories filed a Form 6-K on July 1, 2026, to furnish an intimation (Exhibit 99.1) to the SEC. The filing is a routine foreign issuer report with no material financial disclosures, business updates, or operational changes. The attached document content is not available for review, so the analysis is based solely on the filing metadata.

Key Facts

  • Form 6-K filed July 1, 2026, as a routine foreign private issuer report
  • Exhibit 99.1 is an intimation dated July 1, 2026, content of this exhibit is unavailable
  • No financial results, guidance, material agreements, or operational updates disclosed in the filing
  • Company has 834,656,970 equity shares outstanding per recent 20-F filing (May 29, 2026)
  • Analysis based on filing metadata only, document content was unavailable

Financial Impact

No financial figures disclosed in this filing

Risk Factors

  • Lack of document content limits visibility into the substance of the intimation filed as Exhibit 99.1
  • No forward-looking guidance or strategic commentary provided in the filing

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000475
Document: 0001575872-26-000475-index.html0001575872-26-000475
Document: 0001575872-26-000475.txt0001575872-26-000475

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 1, 2026